Comparative Pharmacology
Head-to-head clinical analysis: DOCIVYX versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOCIVYX versus RESPORAL.
DOCIVYX vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Docivyx is a docetaxel formulation; it binds to tubulin, promoting assembly of microtubules and inhibiting depolymerization, leading to cell cycle arrest and apoptosis.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
75 mg/m2 intravenously over 1 hour every 3 weeks.
2 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 24-48 hours; prolonged with hepatic impairment.
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Primarily hepatic metabolism followed by biliary excretion; <10% excreted unchanged in urine.
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic